ClinicalTrials.gg
CompletedNCT06115603CBGUpdated Nov 19, 2026

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

A Phase 2 interventional study of Cannabigerol and Placebo in Attention-Deficit/Hyperactivity Disorder, sponsored by University of Arkansas, Fayetteville. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Arkansas, Fayetteville · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now CompletedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
366th of 706
67 · median 70
Started
2024
with 31 others
Phase 2
80 of 807
3 open now
Registered
710th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 366th largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2024, is one of 80 in phase 2, and was the 710th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes (PANAS only) and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.

03

Conditions studied

  • Attention-Deficit/Hyperactivity Disorder
04

Who can participate

The criteria were revised on the registry on Nov 19, 2026. See what changed

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  1. Between 18 and 55-years-old.
  2. between 18 and 35 kg/m2.
  3. Score a 2 or above on the Adult ADHD Self-Report Scale (ASRS) Symptom Checklist Part A or have an official ADHD diagnosis.
  4. Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND (with the exception that they do not need to exhibit symptoms before age 12).
  5. Are not pregnant or currently breastfeeding.
  6. Have no history of significant allergic condition, , or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
  7. Have not used CBG or any other cannabinoid products in the past 30 days.
  8. Willing to abstain from using cannabis or any THC-containing product for the duration of the study.
  9. Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2).
  10. Have not been exposed to any drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study.
  11. Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study.
  12. Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months.
  13. Not currently having thoughts of committing suicide
  14. Does not meet criteria for current severe major depressive disorder or a substance use disorder.
  15. Have not been diagnosed with bipolar disorder or psychosis.
  16. Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic).
  17. Do not have history of diagnosis related to liver function and/or significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis).
  18. Willing to ensure they have used effective (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion.
  19. Have access to a ride to the University of Arkansas campus for research appointments.
  20. Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing).
  21. Do not have any serious or unstable physical health conditions including neurological or renal illness.
  22. Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block.
  23. No atrial fibrillation, bradycardia, or tachycardia detected via mobile during the in-laboratory visit.
  24. No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit.
  25. Not currently prescribed or taking the following medications:

    • Warfarin
    • Clobazam
    • Valproic acid
    • Phenobarbital
    • Mechanistic Target of Rapamycin [mTOR] Inhibitors
    • Oral tacrolimus
    • St. John's wort
    • Epidiolex
    • Escitalopram
    • Cardiovascular medications
    • Strong inhibitors (e.g., ketoconazole)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Active comparator
    Cannabigerol

    1mL of 80mg of Cannabigerol. Cannabigerol is a safe, legal, non-high-inducing cannabinoid obtained from the cannabis plant.

    Drug: Cannabigerol

  • Placebo comparator
    Placebo

    1mL of Placebo. Placebo is made in the form of MCT oil.

    Other: Placebo

Interventions

  • 1 mL of 80mg Cannabigerol once during experimental session

  • OtherPlacebo

    1 mL of placebo once during experimental session

06

What researchers measure

Primary outcomes

  1. Sustained Attention to Response Task

    A computerized task that measures response inhibition.

    Time frame: 75 minutes post CBG/placebo administration

  2. Trail Making Test-Parts A and B (TMT-A&B)

    A paper-and-pencil task that measures attention, psychomotor speed, and cognitive flexibility.

    Time frame: 75 minutes post CBG/placebo administration

  3. Digit Symbol Substitution Test (DSST)

    A paper-and-pencil task that measures attention/processing speed.

    Time frame: 75 minutes post CBG/placebo administration

  4. Rey Auditory Verbal Learning Test (AVLT)

    A paper-and-pencil/verbal test that measures verbal memory.

    Time frame: 75 minutes post CBG/placebo administration

  5. Iowa Gambling Task (IGT)

    A computerized task that measures decision making (an indicator of impulsivity/hyperactivity).

    Time frame: 75 minutes post CBG/placebo administration

Secondary outcomes

  1. Positive and Negative Affect Scale-Expanded Version

    Self-report measure of positive and negative affect. Scores range from 30-150 on each of the two types of affects, with higher scores representing greater affect.

    Time frame: Baseline, 45 minutes post CBG/placebo administration, 75 minutes post CBG/placebo administration

  2. Karolinska Sleepiness Scale

    Self-report measure of subjective level of sleepiness at a particular time during the day. Scores range from 1-10, with higher scores representing greater sleepiness.

    Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration

  3. Brief Irritability Test

    Self-report measure of irritability. Scores range from 5-30, with higher scores representing greater irritability.

    Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration

  4. Numeric Rating Scale (pain)

    Self-report measure of subjective level of pain. Scores range from 0-10, with higher scores representing greater pain.

    Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration

  5. State-Trait Anxiety Inventory (State Version)

    Self-report measure of state anxiety. Scores range from 20 to 80 with higher scores indicating greater anxiety.

    Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration

  6. Visual Analog Scales

    Self-report of state-like states (e.g., anxiety, hunger). This scale ranges from 0 to 100 with higher scores indicating higher levels of the indication.

    Time frame: 75 minutes post CBG/placebo administration

  7. Global Impression of Change

    Self-report measure of perceived change in ADHD symptoms. This scale ranges from 1 to 7 with higher scores indicating greater improvements.

    Time frame: 75 minutes post CBG/placebo administration

07

Study locations

1 site
  • University of Arkansas
    Fayetteville, Arkansas 72703, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified, individual participant data (including data dictionaries) that underlie results reported in each published report will be shared (text, tables, figures, appendices)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 9months and ending 36 months following publication

Access criteria: Researchers who provide a methodologically sound proposal. Inquiries should be directed to eleenfe@uark.edu; Requestors will need to sign a data agreement to gain access

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jul 2026, 19 months.

Of 40 phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 40. This study's 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Nov 3, 2023
StartActual
Dec 14, 2024
Primary completionActual
Jul 15, 2026
CompletionActual
Jul 30, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 4, 2026
Enrollment
76 (estimated)→67 (actual)
Nov 4, 2026
Eligibility
Criteria revised in 2 updates
What changed on Nov 9, 2026
  • EditedScore a 42 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A or have an official ADHD diagnosis.
What changed on Nov 19, 2026
  • EditedMeet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND (with the exception that they do not need to exhibit symptoms before age 12).
across 2 updates, Nov 9, 2026 – Nov 19, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionTrail Making Test-Parts A and B (TMT-A&B): how it is measured was reworded
Nov 9, 2026
Show all 3 updates
  1. Nov 19, 2026
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedMeet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND (with the exception that they do not need to exhibit symptoms before age 12).
    + 1 other change: design details
  2. Nov 9, 2026
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedScore a 42 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A or have an official ADHD diagnosis.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionTrail Making Test-Parts A and B (TMT-A&B): how it is measured was reworded
    + 1 other change: description
  3. Nov 4, 2026
    Recruiting→Completed
    Enrollment 76 (estimated)→67 (actual)
    + 4 other changes: verification date, date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06115603
Lead sponsor
University of Arkansas, Fayetteville
Responsible party
Ellen Leen-Feldner (Professor, University of Arkansas, Fayetteville) — Principal investigator
First posted
Nov 3, 2023
Start date
Dec 14, 2024
Primary completion
Jul 15, 2026
Completion
Jul 30, 2026
Last update
Nov 19, 2026

Study contacts

Ellen W Leen-Feldner, PhD
principal investigator · University of Arkansas

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabigerol

Start the discussion